Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac hypertrophy and hypertension

F G Dunn1

  • 1Cardiac Department, Stobhill Hospital NHS Trust, Glasgow, UK.

Blood Pressure. Supplement
|January 1, 1995
PubMed
Summary

Left ventricular hypertrophy (LVH) in hypertension is a known cardiovascular risk. While advances improve understanding and management, the impact of LVH regression on overall risk requires further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Winning hearts and minds: ECG reporting in the first seizure clinic.

BMC cardiovascular disorders·2021
Same author

Adopting seven-day working in practice: a report by the Royal College of Physicians and Surgeons of Glasgow.

Scottish medical journal·2014
Same author

Limited clinical utility of CT coronary angiography in a district hospital setting.

QJM : monthly journal of the Association of Physicians·2010
Same author

The burden of atrial fibrillation in unselected acute medical admissions.

Scottish medical journal·2008
Same author

Pericardiocentesis practice in the United Kingdom.

International journal of clinical practice·2007
Same author

Key issues in the management of atrial fibrillation--protecting the patient and controlling the arrhythmia.

Scottish medical journal·2007

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Medicine

Background:

  • Left ventricular hypertrophy (LVH) is a significant cardiovascular risk factor in hypertensive patients.
  • Recent years have seen advances in understanding LVH pathophysiology, detection, and management, including hypertrophy regression.
  • Key factors contributing to myocyte hypertrophy include stretch, angiotensin II, and sympathetic nervous system stimulation.

Purpose of the Study:

  • To review the current understanding of left ventricular hypertrophy (LVH) in hypertension.
  • To discuss advances in the pathophysiology, detection, and management of LVH.
  • To explore the mechanisms of increased mortality and the role of LVH regression.

Main Methods:

  • Literature review of epidemiological, pathophysiological, and clinical studies on LVH in hypertension.
  • Comparison of diagnostic methods for LVH, specifically echocardiography and ECG.
  • Analysis of factors contributing to myocyte and fibroblast proliferation.

Main Results:

  • Trophic factors like angiotensin II and sympathetic stimulation drive myocyte hypertrophy.
  • Aldosterone and angiotensin contribute to fibroblast proliferation.
  • Echocardiography is more reliable than ECG for LVH detection, though both are complementary.

Conclusions:

  • Mechanisms of increased mortality in LVH patients, including ischemia, dysfunction, and arrhythmias, are under investigation.
  • Optimal blood pressure control is crucial.
  • The specific impact of LVH regression on morbidity and mortality requires further clinical trials.

Related Experiment Videos